Table 2 Visual acuity at 3- and 5 years by quartile.

From: Evaluating the long-term predictive value of macular thickness fluctuations on diabetic macular oedema response to anti-VEGF treatment

 

Quartile 1

Quartile 2

Quartile 3

Quartile 4

p-value

Baseline BVA

 3 year

45.1 ± 26.6

53.1 ± 11.1

43.7 ± 23.8

43.9 ± 23.4

0.09

 5 year

47.9 ± 26.6

50.6 ± 21.5

45.2 ± 24.0

43.1 ± 21.8

0.47

Final BVA

 3 year

58.3 ± 28.0

66.9 ± 23.1

52.2 ± 22.3

45.3 ± 22.8

<0.001

 5 year

55.3 ± 28.2

60.3 ± 26.0

55.3 ± 22.8

43.2 ± 27.8

0.06

Change in BVA

 3 year

12.5 ± 29.0

13.9 ± 28.1

8.52 ± 25.2

1.02 ± 26.8

0.21

 5 year

7.94 ± 31.6

10.33 ± 30.0

9.50 ± 29.5

0.83 ± 31.7

0.63

Final CST

 3 year

288 ± 102

310 ± 69.5

302 ± 88.6

321 ± 134

0.07

 5 year

292 ± 79.4

294 ± 93.4

286 ± 88.1

292 ± 150

0.74

Change in CST

 3 year

−70.6 ± 210

−100 ± 107

−112 ± 113

−133 ± 176

0.01

 5 year

−56.5 ± 173

−100 ± 92.3

−123 ± 121

−126 ± 153

<0.01

  1. Data are presented as mean ± SD. Statistical significance is denoted by p < 0.05 and bolded (Kruskal–Wallis multiple comparisons with Dunn’s post-hoc analysis).
Back to article page